We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Synovial Fluid NGAL Accurately Diagnoses Prosthetic Joint Infection

By LabMedica International staff writers
Posted on 04 Oct 2022
Print article
Image: Neutrophil gelatinase-associated lipocalin (NGAL) Duo Set ELISA (Photo courtesy of R&D Systems)
Image: Neutrophil gelatinase-associated lipocalin (NGAL) Duo Set ELISA (Photo courtesy of R&D Systems)

Prosthetic joint infection (PJI) is a serious complication that is difficult to diagnose after joint arthroplasty and seriously affects the physical and mental health of patients. Current studies suggest that PJI is a relatively limited infectious disease, and the synovial fluid (SF) biomarkers more directly reflect the nature and extent of inflammation.

The previous use of antimicrobial therapies will significantly decrease the sensitivities of either serum or the synovial fluid (SF) biomarkers. Inaccurate diagnosis may lead to incorrect treatment options and poor prognosis. Neutrophil gelatinase-associated lipocalin (NGAL) has been used for the early identification of bacterial and viral infections in blood and cerebrospinal fluid.

Orthopaedic Surgeons at the Fujian Medical University (Fuzhou, China) included in a prospective study in a single osteoarticular infection referral center, in which consecutive patients who needed revision surgery after hip and knee arthroplasty due to PJI or aseptic prosthesis loosening from January 2017 to September 2018. A total of 78 patients who underwent hip or knee revision surgery were included in the study.

The scientists collected 0.5 mL of the SF for the white blood cell count (SF-WBC) and neutrophil classification. A total of 1 mL of the SF was frozen at -80 °C for NGAL determination. The remaining SF was used for microbiological culture. SF was injected into Bactec Plus/F aerobic or Bactec Peds Plus/F blood culture bottles and anaerobic blood culture bottles (Becton-Dickinson, Heidelberg Germany). The plates and bottles were incubated for 14 days in a Bactec 9050 automatic incubator.

The periprosthetic tissue was cut into pieces, added to the broth for grinding, and then cultured for aerobic and anaerobic bacteria on a blood plate for 14 days. The Vitek II system (bioMérieux, Durham, NC, USA) was used for microbial identification and antibiotic susceptibility testing. The SF samples were centrifuged and diluted appropriately before assaying. The team determined NGAL levels using the NGAL Duo Set ELISA Kits (R&D Systems, Minneapolis, MN, USA). The level of NGAL in the SF was measured in duplicate.

The investigators reported that a total of 50 of 78 included patients were diagnosed with PJI. A total of 40 cases were positively cultured. The most common pathogen was Staphylococcus aureus in 10 (25%) patients, followed by coagulase-negative staphylococci in seven patients, and gram-negative bacilli in seven patients (17.5%), and other pathogens in 16 patients. The median SF-NGAL level was 3,633 ng/mL (interquartile range [IQR], 1,332-10,737) in the PJI group and 26.8 ng/mL (IQR, 12.4-52.5) in the aseptic failure group. When the SF-NGAL threshold was 263 ng/mL, the area under the curve was 0.98, the sensitivity was 92.9%, and the specificity was 98%. The median level was 5,779 ng/mL (IQR, 1425-13,072) in the antibiotic group and 2,590 ng/mL (IQR, 932-8,970) in the non-antibiotic group.

The authors concluded that NGAL in the SF has both high sensitivity and specificity for the PJI diagnostics. The previous use of antibiotics does not affect the level of the SF-NGAL. The SF-NGAL can be used as a potential laboratory indicator for diagnosing PJI. The study was published on October 1, 2022 in the International Journal of Infectious Diseases.

Related Links:
Fujian Medical University 
Becton-Dickinson 
bioMérieux 
R&D Systems 

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Aspergillus Test
REALQUALITY Aspergillus

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.